Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RORC | P51449 | 15/20 | 0.41 |
| ▸ | STS | P08842 | 1/20 | 0.40 |
| ▸ | PARP1 | P09874 | 1/20 | 0.38 |
| ▸ | KDM1A | O60341 | 1/20 | 0.37 |
| ▸ | MAOB | P27338 | 1/20 | 0.37 |
| ▸ | CETP | P11597 | 1/20 | 0.35 |
| ▸ | CCRL2 | O00421 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28801609 | 1.00 | RORC (0.41) | RORCSTSPARP1KDM1AMAOB | |
| SCHEMBL1498339 | 0.86 | RORC (0.45) | RORC | |
| SCHEMBL1498353 | 0.85 | CETP (0.40) | RORCCETP | |
| SCHEMBL1498351 | 0.85 | CETP (0.40) | RORCCETP | |
| SCHEMBL1498438 | 0.81 | TACR1 (0.37) | RORCSTSCETP | |
| SCHEMBL1498343 | 0.81 | TACR1 (0.37) | RORCSTSCETP | |
| SCHEMBL12692914 | 0.81 | CETP (0.36) | RORCCETP | |
| SCHEMBL1498421 | 0.80 | RORC (0.35) | RORCSTS | |
| SCHEMBL1498420 | 0.80 | RORC (0.35) | RORCSTS | |
| SCHEMBL12543508 | 0.79 | CACNA1B (0.41) | RORCCETP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120245137-A1 | ARYL SULPHONE DERIVATIVES AS CALCIUM CHANNEL BLOCKERS | ZALICUS PHARMACEUTICALS LTD. (CA) | 2012-09-27 | — | — | US | disclosed |
| US-20120245137-A1 | ARYL SULPHONE DERIVATIVES AS CALCIUM CHANNEL BLOCKERS | ZALICUS PHARMACEUTICALS LTD. (CA) | 2012-09-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120245137-A1 | ARYL SULPHONE DERIVATIVES AS CALCIUM CHANNEL BLOCKERS | CACNA1I, CACNA1G, CACNA1A | RORC 1695/4885STS 196/4885PARP1 4752/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.